{"doi":"10.1016/j.ejphar.2005.04.010","title":"Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue","abstract":null,"journal":"European Journal of Pharmacology","year":2005,"id":687515,"datarank":0.7312795984801728,"base_score":4.875197323201151,"endowment":4.875197323201151,"self_citation_contribution":0.7312795984801728,"citation_network_contribution":0.0,"self_endowment_contribution":0.7312795984801728,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":130,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":2,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":409032,"name":"Ana M. Sánchez","orcid":"0000-0002-9119-7624","position":1,"is_corresponding":false},{"id":1796094,"name":"Beatriz Collado","orcid":null,"position":2,"is_corresponding":false},{"id":1796095,"name":"Sophie Malagarie-Cazenave","orcid":null,"position":3,"is_corresponding":false},{"id":1796096,"name":"Nuria Olea","orcid":null,"position":4,"is_corresponding":false},{"id":1796097,"name":"María J. Carmena","orcid":null,"position":5,"is_corresponding":false},{"id":1796098,"name":"Juan C. Prieto","orcid":null,"position":6,"is_corresponding":false},{"id":1796099,"name":"Inés Díaz-Laviada","orcid":null,"position":7,"is_corresponding":false},{"id":1796093,"name":"María G. Sánchez","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue","abstract":"Vanilloid receptor subtype-1 (TRPV1), the founding member of the vanilloid receptor-like transient receptor potential channel family, is a non-selective cation channel that responds to noxious stimuli such as low pH, painful heat and irritants. In the present study, we show, as means of reverse transcriptase-polymerase chain reaction and Western blot analysis, that the vanilloid TRPV1 receptor is expressed in the prostate epithelial cell lines PC-3 and LNCaP as well as in human prostate tissue. The kinetic parameters inferred from [(125)I]-resiniferatoxin binding were in concordance with data of TRPV1 receptors expressed in other tissues. The contribution of the endogenously expressed TRPV1 channel to intracellular calcium concentration increase in the prostate cells was studied by measuring changes in Fura-2 fluorescence by fluorescence microscopy. Addition of capsaicin, (R)-methanandamide and resiniferatoxin to prostate cells induced a dose-dependent increase in the intracellular calcium concentration that was reversed by the vanilloid TRPV1 receptor antagonist capsazepine. These results indicate that the vanilloid TRPV1 receptor is expressed and functionally active in human prostate cells.","is_dataset_classified":null,"base_score":4.875197323201151,"endowment":4.875197323201151,"datacite_reuse_total":2,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"15913603","pmcid":null,"openalex_id":"https://openalex.org/W2011631371","authors":[],"funders":[],"total_grants":0,"fwci":1.886,"citation_percentile":0.84475939,"influential_citations":0,"citation_trend":[{"year":2012,"count":9},{"year":2013,"count":5},{"year":2014,"count":12},{"year":2015,"count":5},{"year":2016,"count":11},{"year":2018,"count":6},{"year":2019,"count":2},{"year":2020,"count":12},{"year":2021,"count":5},{"year":2022,"count":5},{"year":2023,"count":5},{"year":2024,"count":5},{"year":2025,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0014299905004073?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0014299905004073?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ejphar.2005.04.010","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/15913603","host_type":"repository"}],"fields_of_study":["Ion Channels and Receptors","Pain Mechanisms and Treatments","Connexins and lens biology","Arachidonic Acids","Binding, Competitive","Blotting, Western","Calcium","Capsaicin","Cell Line, Tumor","Diterpenes","Dose-Response Relationship, Drug","Gene Expression","Humans","Iodine Radioisotopes","Ion Channels","Male","Prostate","Prostatic Neoplasms","Radioligand Assay","Reverse Transcriptase Polymerase Chain Reaction","TRPV Cation Channels"],"mesh_terms":["Arachidonic Acids","Binding, Competitive","Calcium","Capsaicin","Diterpenes","Dose-Response Relationship, Drug","Humans","Iodine Radioisotopes","Ion Channels","Male","Prostate","Prostatic Neoplasms","Radioligand Assay","Blotting, Western","Gene Expression","Reverse Transcriptase Polymerase Chain Reaction","Cell Line, Tumor","TRPV Cation Channels"],"keywords":["Resiniferatoxin","Capsazepine","TRPV1","LNCaP","Transient receptor potential channel","Chemistry","TRPV","Receptor","Capsaicin","Prostate cancer","Endocrinology","Internal medicine","Biology","Biochemistry","Medicine","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.13290575.v1","title":"Additional file 1 of Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.13290575","title":"Additional file 1 of Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T22:08:23.994090Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}